SoticleSTAT 是一种首创的、口服有活性的胆固醇 24-羟化酶 (cholesterol 24-Hydroxylase, CH24H) 选择性抑制剂。它可用于研究癫痫综合征。

Soticlestat is a potent, selective and orally active cholesterol 24-hydroxylase (CYP46A1) inhibitor. It has the potential for epilepsy syndromes research.

Soticlestat inhibits the catalytic activity of human cholesterol 24-hydroxylase (CH24H) in a concentration-dependent manner with an IC50?of 4.5 nM

Soticlestat treatment lowers brain 24S-hydroxycholesterol in a dose-dependent manner and substantially reduceds premature deaths of APP/PS1-Tg mice at a dose lowering brain 24S-hydroxycholesterol by approximately 50%. Soticlestat can suppress potassium-evoked extracellular glutamate elevations in the hippocampus

1429505-03-2

C23H23N3O2

373.456

TAK-935;OV935

DMSO:100 mg/mL (267.77 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years